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1. Introduction 
The physiological response of the neuromuscular 
junction, or of the fish electroplaque, to acetylcholine 
(ACh) is blocked by two distinct classes of pharma- 
cological agents [ 11. The competitive antagonists such 
as d-tubocurarine or flaxedil bind at the level of (or 
close to) the receptor site for acetylcholine where they 
block the effect of the agonists possibly by steric hin- 
drance. This site is also labelled by snake venom 
a-toxins 123 and the covalent affinity labelling 
reagents: TDF [3,4]; MPTA [S]; bromoacetylcholine 
[6]; DAPA [7]. Another rather heterogeneous group 
of compounds includes the aminated local anesthetics 
[1,8] and the frog toxin, histrionicotoxin [9,10], 
which block the response to ACh in a non-competitive 
manner. In vitro studies carried out with radioactive 
[8,1 l-131 or fluorescent [12,14-181 ligands have 
shown that these non-competitive blockers bind to a 
class of sites distinct from the ACh-receptor site [ 11, 
121. Moreover, at equilibrium [ 121 or after rapid 
mixing [ 14,17,18] the two classes of sites have been 
shown to interact in an allosteric manner. Biophysical 
experiments suggest hat these non-competitive 
blockers bind directly to the ion gate opened by ACh 
[ 19,201, although indirect effects are also possible 
[21]. In any case, compounds of this series behave as 
Abbreviations: ACh, acetylcholine; TDF, p-trimethylammo- 
nium benzene diazonium fluoroborate; MPTA, 4-(N-male- 
imido) phenyltrimethylammonium; DAPA, bis(3_azidopyridi- 
nium)-l,lO-decane perchlorate; TLC, thin-layer chromatog- 
raphy; NMR, nuclear magnetic resonance; HMDS, hexamethyl- 
disiloxane 
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potential labels of the ion translocating device, or 
ionophore, regulated by ACh. 
In an attempt to label the site for non-competitive 
blockers on Torpedo receptor-rich membranes, a 
photoaffinity labelling derivative of the local anes- 
thetic procaine (procaineamide azide) was synthetized 
[22]. This compound covalently labels [22] the 
43 000 Mr polypeptide recently discovered in the ACh 
receptor-rich membranes [23]. However, removal of 
this 43 000 Mr polypeptide by pH 11 treatment does 
not interfere with the reversible binding of the radio- 
active local anesthetic [ 14C] meproadifen, and with 
the allosteric interaction between ACh receptor site 
and local anesthetic binding site [24] indicating that 
the 43 000 Mr polypeptide and, of course, the site 
labelled by procaine amide azide, are not the site of 
the pharmacological action of the non-competitive 
blockers. 
Here we describe the synthesis of photoaffinity 
derivatives of two potent non-competitive blockers of 
the electroplaque synapse: dimethisoquin [ 11,121 and 
trimethisoquin [ 131. These compounds 5 and 7-azido 
dimethisoquin and S-azido trimethisoquin behave as 
irreversible blockers of the response of Electrophoms 
electricus electroplaque to cholinergic agonists. In 
[25] the selective labelling by [3H]azido 5trimethi- 
soquin of some of the polypeptide chains present in 
Torpedo ACh receptor-rich membranes is described. 
2. Material and methods 
2.1. Synthesis 
The synthesis of the azide compounds was per- 
formed as shown in scheme 1. 
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3-n-butyl-S-nitro-I -(2-(dimethylamino)ethox_v] 
isoquinoline, II 
and 
3-n-butyl-7-nitro-1-(2-(dimethylamino)ethoxy] 
isoquinoline, III 
Potassium nitrate, 656 mg (6.48 mmol) was added 
at 0°C to a solution of 2 g (6.48 mmol) dimethisoquin 
(I) in 8 ml sulfuric acid (d = 1.84). The mixture was 
stirred for 48 h at room temperature. The resulting 
solution was poured onto ice, treated with 12 N 
NaOH to pH 11 and extracted 3 times with 50 ml 
ethyl acetate. The organic phases were dried on 
Na2S0, and evaporated to dryness in vacua giving 
2.1 g residual oil. The oil was purified by chromatog- 
raphy on silica gel column using diethyloxide as eluent. 
The oily 7-nitro derivative (III), 346 mg, was eluted 
first. 
Yield: 17%. RF = 0.55 in Et,O:MeOH (1 :l) on silica 
gel plates. 
Anal. talc. for Cr7HZ3N30: C, 64.33; H, 7.3; N, 13.24. 
Found: C, 64.12; H, 7.38; N, 13.15. 
NMR (aromatic part) 6 ppm: Hq, 7.17; He, 7.78; Hg, 
8.26; Hg, 8.88. 
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The oily 5-nitro derivative (II), 840 mg, was then 
eluted. 
Yield: 41$%, RF = 0.40 in Et,O:MeOH (1: 1). 
Anal. found: C, 64.52; H, 7.12;N, 13.35. 
NMR (aromatic part) 6 ppm: H7, 7.38; Hq, 7.55; He, 
8.25; Hs, 8.4. 
3-n-butyl-5amino-l-/2-(dimethylamino) ethoxy] 
isoquinoline dihydrochloride, IV 
and 
3-n-butyl- 7-amino-I-/2-(dimethylamino) ethoxyJ 
isoquinoline dihydrochloride, V 
The nitro derivatives II and III were reduced by 
the Raney-nickel hydrazine hydrate method [26]. 
Raney-nickel was cautiously added in batches over 
30 min to a stirred solution of 3 18 mg (0.96 mM) of 
II and 3 ml hydrazine hydrate in 20 ml EtOH under 
reflux. After 1 h, the solution was cooled down to 
room temperature, and a small amount of Raney- 
nickel was again added to eliminate the excess of 
hydrazine. After 2 h, the solution was filtered and 
evaporated to dryness in vacua. The oily residue was 
precipitated by addition of a solution of HCl in dieth- 
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yloxide. The brown solid was crystallized from 
CH,OH:Et,O (5O:SO) giving (IV) pd = 277 mg, 
F = 178°C; yield, 82%. 
Anal. talc. for Ci7H2#Z12N30: C, 56.67; H, 7.55; Cl: 
19.68; N, 11.66. 
Found: C, 56.25; H, 7.55; Cl, 19.66; N, 11.48. 
NMR 6 ppm: He, 7.17; H7, 7.42; Hg, 7.68; Hs, 8.3. 
Compound V was obtained in the same way by 
Raney-nickel hydrazine hydrate reduction at room 
temperature for 24 h: Yield, 42%; F = 182°C. 
Anal. found: C, 56.32; H, 7.5; Cl, 19.55; N, 11.88. 
NMR 6 ppm: H+ 7.12; Hg, 7.5; Hg, 7.78; Hs, 8.29. 
3-n-butyl-5-azido-I-(2-(dirnethylamino) ethoxy] 
isoquinoline dihydrochloride, VI 
and 
3-n-butyl-7-azido-l-[2-(dimethylamino) ethoxy] 
isoquinoline dihydrochloride, VII 
The two azido compounds VI and VII were syn- 
thetized by the same procedure. Due to the photo- 
sensitive nature of the final compounds, all procedures 
were carried out under a photographic safe light. A 
solution of 50 mg (0.14 mmol) of the amino deriva- 
tives IV or V in 10 ml HZ0 was cooled to 5°C and 
adjusted to pH 1.6 with HCl. Sodium nitrite, 10.6 mg 
(0.15 mmol) was added and the reaction mixture was 
stirred for 1 h below 5°C. After this time, 10.2 mg 
(0.16 mmol) sodium azide were added and the solu- 
tion stirred for 1 h at room temperature. After addi- 
tion of 20 ml CHC13, the solution was adjusted to 
pH 11 with NaOH. The organic layer was separated, 
dried over Na2S04 and evaporated to dryness in 
vacua. The residual oil was dissolved in 10 ml diethyl- 
oxide and the azido compound was precipitated as 
brown solid by addition of 10 ml saturated Et,O:HCl. 
The solid was dried in vacua and its purity was 
checked by TLC and NMR spectroscopy. 
VI: RF = 0.25 in BuOH:AcOH:H20 (4:l: 1). 
NMR 6 ppm; Ha, 7.15; He, 7.35; H7, 7.35; Hs, 7.90. 
VII: RF = 0.3 in BuOH:AcOH:H2 (4: 1: 1). 
NMR 6 ppm; Hq, 7.02; He,, 7.19; Hg, 7.59; Hg, 7.69. 
The presence of the azide group was demonstrated 
by the peak at 2 100 cm-’ in the infrared spectrum 
(not shown). 
3-n-butyl-5-azido-l-[2-(trimethylammonium)ethoxy] 
isoquinoline iodide, VZZI 
The oily basic compound (VI), 50 mg, was dis- 
solved in 10 ml diethyloxide, and 2 ml methyl iodide 
were added. The reaction mixture was stirred for 2 h 
at room temperature giving a precipitate which was 
filtered and dried in high vacuum. 
VII: RF = 0.44 in BuOH:AcOH:H20 (9:0.5:0.5). 
The presence of azido group was demonstrated by 
infrared spectroscopy (fig.1) and the structure deter- 
mined by NMR spectroscopy. In the frequency range 
I I I I I 1 1 1 
3000 2500 2000 1600 1200 cm-1 
Fig.1. Infrared spectra of 5-amino dimethisoquin and S-azido trimethisoquin, recorded in KBr (2 mg product/200 mg KBr). 
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of the N-methyl groups, only one signal at 3 25 ppm 
corresponding to the 9 protons of the trimethyl- 
ammonium group was detected. This indicates that 
the pyridinic nitrogen atom in position 2 was not 
quaternarized because of its steric inhibition by the 
lateral chains located on the carbons 1 and 3. 
2.3. Electrophvsiological measurements 
The pharmacological properties of the photoaffin- 
ity labelling compounds were studied in vivo on the 
electroplaque isolated from the Sachs organ of 
E: electricus by the method in [27]. The ligands were 
applied in a bath on the innervated face of the cell 
and the transmembrane potential recorded with an 
intracellular microelectrode by the method in [ZS]. 
2.3. NMR studies 
‘H NMR spectra were recorded at 80 MHz on a 
Bruker WP 80 spectrometer operating in the CW mode 
and locked to the deuterium resonance of the solvent, 
methanol-d4. The chemical shifts (6 ppm) were mea- 
sured from HMDS as internal reference. 
3. Results and discussion 
3.1. NMR assigmen ts 
Because of their relative instability, the structures 
of the two azido derivatives were established by NMR 
studies on their amino precursors IV and V. As shown 
in fig.2, the spectrum of compound IV shows 4 
aromatic protons. The presence of only one signal (at 
7.42 ppm) with 2 ortho coupling constants indicates 
that the amino group was located on the phenyl ring, 
in the position 5 or 8. The unambiguous characteriza- 
tion of the structure was performed by irradiation of 
the pyridinic signal at 7.17 ppm. This experiment lead 
to the disappearance of the trans-trans stereospecific 
long range coupling constant between H4 and Hs 
[29]. Consequently, the amino group was located on 
the carbon 5. 
The spectrum of V (not shown here) exhibits a 
signal with ortho and meta coupling constants at 
7.5 ppm and a quadruplet with a meta coupling con- 
stant at 8.29 ppm. This signal was transformed into a 
doublet by irradiation of the pyridinic Hq proton, 
and thus corresponds to the H8 proton. Consequently 
the amino group in compound V is located on the 
position 7. 
26 
Fig.2. ‘H NMR spectrum of 5-amino dimethisoquin (aromatic 
protons), recorded at 10-l M in methanol-d4. 
3.2. Pharmacological experiments with E. electricus 
electroplaque 
Figure 3a shows that bath application of lo-’ M 
5-azido dimethisoquin to the innervated face of 
E. electric-us electroplaque caused a decrease of the 
amplitude of the depolarisation elicited by 5 X lo-’ M 
carbamylcholine by 50%; after a 150 min exposure to 
the azide, no significant recovery of the response was 
noticed. In other words, the blocking effect of 5-azido 
dimethisoquin was irreversible. 
Concentration-effect curves established for carb- 
amylcholine after exposure of the electroplaques to 
2 concentrations of 5-azido dimethisoquin showed a 
marked decrease of the maximal response without 
significant change of the apparent dissociation con- 
stant (fig.3b). 
In fig.4, the irreversible blocking of the response to 
carbamylcholine was plotted as a function of the con- 
centration of the various derivatives studied. With all 
of them, the exposure time to the innervated face of 
the electroplaque was 10 min. Half-maximal inhibition 
taking place around 10m5 M for both 5- and 7-azido 
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Eig.3. (a) Bloching effect of 5-azido dimethisoquin on the response to c~bamylcholine of isolated electroplaque from k’. &CWW’. 
The compound was applied in bath for 10 min at 10“ M; then the cell washed with Ringer’s solution. Carbamylchoiine was 
2.5 x lo-’ M. 
[Carbl X lo-” M 
(b) Effect of S-azido trimethisoquin on the dose-response 
curve for ~~bamylcholine, S-azido trimeth~soqu~n was applied 
for 10 min. After 1 h washing with Ringer’s solution, a dose- 
response curve was obtained by applying increasing concen- 
trations of carbamylcholine. 
dimethisoquin and around tW6 M for S-azido tri- 
met~soquin. 
In conclusion, the photoaffinity labelling deriva- 
tives synthesized behave as irreversible blockers of the 
response of E. electricus electroplaque to carbamyl- 
choline. In order to identify their membrane target(s), 
the binding of one of them, 5-azido trimethisoquin, 
was investigated after tritium sabering, with ACh 
receptor-rich membranes from Torperzi, ~r~~ra~~ 
electric organ (see 1251). 
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